With a new computational approach, researchers profiled gene expression rhythms in dozens of tissues from more than 900 individuals for the Genotype-Tissue Expression project.

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

A decline in demand for rapid COVID-19 antigen tests dragged on the company's diagnostics division while lockdowns in China reduced routine testing.

The Franklin Lakes, New Jersey-based firm saw a 17 percent decline in its life sciences business due to an expected drop in COVID-19 testing. 

Molecular lab revenues fell 17 percent during the year, while core lab sales were up 3 percent and point-of-care revenues grew 15 percent. 

Shares of the Seattle-based genomics firm rose as much as 9 percent in Thursday morning trading on the Nasdaq and were up 12 percent over the last two days.

The company reported 1 percent growth in revenues compared to Q2 2022 but said organic revenue growth was 4 percent. 

The companies will jointly develop and commercialize Guardant360 CDx and Guardant360 TissueNext for taletrectinib treatment in advanced and metastatic NSCLC.